Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
cAMP-dependent protein kinase-derived peptide
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
myristoyl-CoA + HIV1 Gag protein N-terminal peptide
N-myristoyl-HIV1 Gag protein N-terminal peptide + CoA
-
-
-
?
myristoyl-CoA + HIV1 Nef protein N-terminal peptide
N-myristoyl-HIV1 Nef protein N-terminal peptide + CoA
-
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
decapeptide, best substrate
-
-
?
myristoyl-CoA + tumor necrosis factor-derived peptide
N-myristoylated tumor necrosis factor-derived peptide + CoA
-
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Gag protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Gag protein N-terminal peptide
tetradecanoyl-CoA + glycyl-HIV1 Nef protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Nef protein N-terminal peptide
lauroyl-CoA + brain acid soluble protein 1
N-lauroyl-brain acid soluble protein 1 + CoA
-
-
N-laurylation of recombinant proteins in Escherichia coli may occur in minimal media
-
?
lauroyl-CoA + c-Src
N-lauroyl-c-Src + CoA
-
N-terminal region of c-Src, residues 1-185
N-laurylation of recombinant proteins in Escherichia coli may occur in minimal media
-
?
myristoyl-CoA + brain acid soluble protein 1
N-myristoyl-brain acid soluble protein 1 + CoA
-
-
-
-
?
myristoyl-CoA + c-Src
N-myristoyl-c-Src + CoA
-
N-terminal region of c-Src, residues 1-185
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
myristoyl-CoA + Gly-Ala-Gln-Phe-Ser-Lys-Thr-Ala-Arg-Arg
N-myristoyl-Gly-Ala-Gln-Phe-Ser-Lys-Thr-Ala-Arg-Arg-derived peptide + CoA
-
i.e. myristolated alanine-rich C-kinase substrate MARCKS
-
-
?
myristoyl-CoA + Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg
N-myristoyl-Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg + CoA
cAMP-dependent protein kinase-derived peptide
-
-
?
myristoyl-CoA + Gly-Cys-Ser-Val-Ser-Lys-Lys-Lys
CoA + N-myristoyl-Gly-Cys-Ser-Val-Ser-Lys-Lys-Lys
-
-
-
?
myristoyl-CoA + Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg
N-myristoyl-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg + CoA
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
myristoyl-CoA + GNAASARR
?
-
-
-
?
myristoyl-CoA + HBV preS1
? + CoA
-
N-myristoylation of HBV preS1 is essential for viral infectivity. HBV preS1 is a fusion protein of hepatitis B virus preS1 with the native-type N-terminus and a His6-Tag fused to C-terminus
-
-
?
myristoyl-CoA + HBV preS1-HT
? + CoA
-
fusion protein of hepatitis B virus preS1 with the native-type N-terminus and a His6-Tag fused to C-terminus
-
-
?
myristoyl-CoA + HIV-1 Nef protein
?
-
myristoylation results in conformational changes in HIV-1 Nef
-
-
?
myristoyl-CoA + HIV-1 negative regulatory factor
N-myristoyl-HIV-1 negative regulatory factor + CoA
-
-
-
?
myristoyl-CoA + HIV1 Gag protein N-terminal peptide
N-myristoyl-HIV1 Gag protein N-terminal peptide + CoA
-
-
-
?
myristoyl-CoA + HIV1 Nef protein N-terminal peptide
N-myristoyl-HIV1 Nef protein N-terminal peptide + CoA
-
-
-
?
myristoyl-CoA + M2 gene segment of reovirus type 3-derived peptide
N-myristoylated M2 gene segment of reovirus type 3-derived peptide + CoA
-
i.e. Gly-Asn-Ala-Ser-Ser-Ile-Lys-Lys-Lys
-
-
?
myristoyl-CoA + Nef
? + CoA
-
Nef forms a stable complex specifically with N-myristoyltransferase isoform 1. The association requires an Nterminal region of Nef containing an intact myristoylation signal and represents a transient intermediate of the myristoylation reaction
-
-
?
myristoyl-CoA + Nef protein
CoA + N-myristoyl-Nef protein
-
HIV-1 accessory protein Nef, usage of C-terminally 6xHis-tagged Nef SF2
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
myristoyl-CoA + peptide CAP5.5
CoA + N-myristoyl-peptide CAP5.5
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein
-
-
?
myristoyl-CoA + peptide Hs pp60src(2-9)
CoA + N-myristoyl-peptideHs pp60src(2-9)
-
-
-
-
?
myristoyl-CoA + tumor necrosis factor-derived peptide
N-myristoylated tumor necrosis factor-derived peptide + CoA
-
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Gag protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Gag protein N-terminal peptide
tetradecanoyl-CoA + glycyl-HIV1 Nef protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Nef protein N-terminal peptide
tetradecanoyl-CoA + glycyl-pp60c-Src
CoA + N-tetradecanoyl-glycyl-pp60c-Src
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
additional information
?
-
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
N-myristoylation is a process of covalent irreversible protein modification that promotes association of proteins with membranes
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Gag protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Gag protein N-terminal peptide
-
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Gag protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Gag protein N-terminal peptide
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Nef protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Nef protein N-terminal peptide
-
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Nef protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Nef protein N-terminal peptide
i.e. myristoyl-CoA, NMT2 has approximately 5fold higher catalytic efficiency for the myristoylation of Nef than NMT1
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
-
-
?
myristoyl-CoA + cAMP-dependent protein kinase-derived peptide
N-myristoylated cAMP-dependent protein kinase-derived peptide + CoA
-
i.e. Gly-Asn-Ala-Ala-Ala-Ala-Lys-Lys-Arg-Arg
-
-
?
myristoyl-CoA + Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg
N-myristoyl-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg + CoA
-
pp60src-derived peptide
-
?
myristoyl-CoA + Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg
N-myristoyl-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-Arg + CoA
-
pp60src-derived peptide
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
specific for Gly at N-terminus
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
-
the enzyme plays a major role in the process of myristoylation of oncoproteins including the c-src family
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
N-myristoylation is a process of covalent irreversible protein modification that promotes association of proteins with membranes
-
-
?
myristoyl-CoA + glycylpeptide
N-myristoylglycylpeptide + CoA
cross talk between enzyme and protein substrate
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
-
-
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
-
hexadecapeptide from N-terminus
-
?
myristoyl-CoA + p60src-derived peptide
N-myristoylated p60src-derived peptide + CoA
decapeptide, best substrate
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Gag protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Gag protein N-terminal peptide
-
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Gag protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Gag protein N-terminal peptide
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Nef protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Nef protein N-terminal peptide
-
-
-
?
tetradecanoyl-CoA + glycyl-HIV1 Nef protein N-terminal peptide
CoA + N-tetradecanoyl-glycyl-HIV1 Nef protein N-terminal peptide
i.e. myristoyl-CoA, NMT2 has approximately 5fold higher catalytic efficiency for the myristoylation of Nef than NMT1
-
-
?
tetradecanoyl-CoA + glycyl-pp60c-Src
CoA + N-tetradecanoyl-glycyl-pp60c-Src
-
-
-
-
?
tetradecanoyl-CoA + glycyl-pp60c-Src
CoA + N-tetradecanoyl-glycyl-pp60c-Src
-
i.e. myristoyl-CoA
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
-
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
covalent attachment of the myristoyl group, generally to the N-terminal glycine residue of proteins. N-myristoylation occurs absolutely on an exposed N-terminal glycine and on a general consesus motif of GXXXS/T, where X is any amino acid
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
posttranslational transfer of a C14 saturated fatty acid (myristic acid) from myristoyl-CoA to the N-terminal glycine residue of target proteins
-
-
?
tetradecanoyl-CoA + glycylpeptide
CoA + N-tetradecanoylglycylpeptide
-
transfer of a C14 saturated fatty acid (myristic acid) from myristoyl-CoA to the N-terminal glycine residue of target proteins
-
-
?
additional information
?
-
ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
-
ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
N-myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef, overview
-
-
?
additional information
?
-
N-myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef, overview
-
-
?
additional information
?
-
-
N-myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef, overview
-
-
?
additional information
?
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
NMT1 is critical for tumor cell proliferation. Ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
NMT1 is critical for tumor cell proliferation. Ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
-
NMT1 is critical for tumor cell proliferation. Ablating NMT1 is more effective in inhibiting tumor growth than is ablation of NMT2
-
-
?
additional information
?
-
-
isozyme NMT1 catalyzes myristoylation of various proteins crucial in signal transduction, cellular transformation, and oncogenesis
-
-
?
additional information
?
-
-
strong interaction of NMT2 with caspase-3 with a probable major role in the cellular regulation of NMT2, caspase-3 interaction with NMT2 is stronger than with NMT1. The cellular regulation of NMT1 and NMT2 is mediated by two different signaling molecules, m-calpain and caspase, respectively, overview. Protein-protein interaction of NMT forms and p53
-
-
?
additional information
?
-
N-myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef, overview
-
-
?
additional information
?
-
N-myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef, overview
-
-
?
additional information
?
-
-
N-myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef, overview
-
-
?
additional information
?
-
-
development of a robust sensitive fluorescence-based assay method to study the enzymatic activity of NMT1 and NMT2 based on detection of CoA by 7-diethylamino-3-(4-maleimido-phenyl)-4-methylcoumarin, overview
-
-
?
additional information
?
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
-
N-myristoylation of the synthetic peptide CAP5.5, derived from the N-terminus of the Trypanosoma brucei CAP5.5 protein, with myristoyl-CoA
-
-
?
additional information
?
-
NMT acts both as N-terminal lysine and glycine myristoyltransferase
-
-
-
additional information
?
-
-
NMT acts both as N-terminal lysine and glycine myristoyltransferase
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide
-
1-(5-[3,4-difluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl]-1-methyl-1H-indazol-3-yl)-N,N-dimethylmethanamine
-
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide
-
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile
-
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole
-
ethyl 4-(ethylsulfanyl)-6-([6-[(piperidin-4-yl)amino]pyridin-3-yl]methoxy)quinoline-3-carboxylate
-
ethyl 4-(ethylsulfanyl)-6-[(6-[[(3R)-pyrrolidin-3-yl]amino]pyridin-3-yl)methoxy]quinoline-3-carboxylate
-
ethyl 4-(ethylsulfanyl)-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
ethyl 6-(benzyloxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
ethyl 6-([6-[(2-aminoethyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
ethyl 6-([6-[(3-aminopropyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
HIV1 Nef protein N-terminal peptide
Nef peptide acts as a competitive inhibitor for the myristoylation of Gag
-
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine
-
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide
-
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3R,4S)-3-(hydroxymethyl)-4-(4-methoxyphenyl)pyrrolidin-1-yl]butan-1-one
-
(3R)-3-amino-4-(4-chlorophenyl)-1-[(3S,4R)-3-(4-chlorophenyl)-4-(hydroxymethyl)pyrrolidin-1-yl]butan-1-one
-
1,12-dodecanedicarboxylic acid
IC50 above 100 mM
1,3-dimyristoylglycerol
IC50 above 100 mM
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-(2,4-difluorobenzyl)azetidine-3-carboxamide
-
1-(5-chloro-2-[[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]azetidine-3-carboxamide
-
1-(5-[3,4-difluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl]-1-methyl-1H-indazol-3-yl)-N,N-dimethylmethanamine
-
1-myristoyl-rac-glycerol
IC50 in the range 1-100 mM
1-Tetradecanal
IC50 in the range 1-100 mM
1-Tetradecanol
IC50 above 100 mM
2,6-dichloro-4-[2-(piperazin-1-yl)pyridin-4-yl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
-
-
2-(4-fluorophenyl)-N-[3-(piperidin-4-yl)-1H-indol-5-yl]acetamide
-
2-dodecylglycidoyl-S-CoA
IC50 below 1 mM
2-[(2-methylpropanoyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
14% inhibition at 0.01 mM
2-[(cyclobutylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
22% inhibition at 0.01 mM
2-[(cyclohexanecarbonyl)amino]-N-[(2-naphthylmethyl)amino]ethyl-benzothiazole-6-carboxamide
49% inhibition at 0.01 mM
2-[(cyclohexylcarbonyl)amino]-N-[3-[(naphthalen-2-ylmethyl)amino]propyl]-1,3-benzothiazole-6-carboxamide
61% inhibition at 0.01 mM
2-[(cyclohexylcarbonyl)amino]-N-[4-[(naphthalen-2-ylmethyl)amino]butyl]-1,3-benzothiazole-6-carboxamide
43% inhibition at 0.01 mM
2-[(cyclohexylcarbonyl)amino]-N-[5-[(naphthalen-2-ylmethyl)amino]pentyl]-1,3-benzothiazole-6-carboxamide
46% inhibition at 0.01 mM
2-[(cyclopentylcarbonyl)amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
32% inhibition at 0.01 mM
2-[[(2,5-dimethoxyphenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
71% inhibition at 0.01 mM
2-[[(2-chloropyridin-3-yl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
16% inhibition at 0.01 mM
2-[[(3,4-dichlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
22% inhibition at 0.01 mM
2-[[(4-chlorophenyl)carbonyl]amino]-N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-1,3-benzothiazole-6-carboxamide
8% inhibition at 0.01 mM
3-(methyl[6-methyl-2-[methyl(1-methylpiperidin-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]amino)propanenitrile
-
3-tetradecyn-1-ol
IC50 above 100 mM
4-[(2-[5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-1,3,4-oxadiazol-2-yl]-1-benzothiophen-3-yl)oxy]piperidine
-
selective and high affinity Plasmodium falciparum inhibitor, pKi value for human enzyme 7.22
5-chloro-2-[[4-(3,5-difluorophenyl)piperidin-1-yl]methyl]-1-methyl-1H-benzimidazole
-
ethyl 4-(ethylsulfanyl)-6-([6-[(piperidin-4-yl)amino]pyridin-3-yl]methoxy)quinoline-3-carboxylate
-
ethyl 4-(ethylsulfanyl)-6-[(6-[[(3R)-pyrrolidin-3-yl]amino]pyridin-3-yl)methoxy]quinoline-3-carboxylate
-
ethyl 4-(ethylsulfanyl)-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
ethyl 4-[(2-cyanoethyl)sulfanyl]-6-[[6-(piperazin-1-yl)pyridin-3-yl]methoxy]quinoline-3-carboxylate
-
ethyl 6-(benzyloxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
ethyl 6-([6-[(2-aminoethyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
ethyl 6-([6-[(3-aminopropyl)amino]pyridin-3-yl]methoxy)-4-(ethylsulfanyl)quinoline-3-carboxylate
-
heat shock cognate protein 70
-
involved in NMT1 regulation, overview
-
histamine
-
noncompetitive
HIV1 Nef protein N-terminal peptide
Nef peptide acts as a competitive inhibitor for the myristoylation of Gag
-
L-histidinol
-
noncompetitive, reversible by L-histidine
lauric acid
IC50 below 1 mM
myristelaidic acid
IC50 below 1 mM
myristic acid
IC50 in the range 1-100 mM
myristoleic acid
IC50 below 1 mM
N(2-S-CoA-tetradecanoyl)glycinamide
IC50 below 1 mM
N,N-dimethyl-1-[5-(2-methylphenyl)-1H-indazol-3-yl]methanamine
-
N-(10-aminodecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
peptidomimetic inhibitor
N-(11-aminoundecanoyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
-
N-(6-[[N-(naphthalen-2-ylmethyl)-b-alanyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
32% inhibition at 0.01 mM
N-(6-[[N-(naphthalen-2-ylmethyl)glycyl]amino]-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
8% inhibition at 0.01 mM
N-myristoyltransferase inhibitor protein 71
-
-
-
N-[(3R)-1-(N-methylglycyl)pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide
-
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-(propanoylamino)-1,3-benzothiazole-6-carboxamide
4% inhibition at 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-([[4-(trifluoromethyl)phenyl]carbonyl]amino)-1,3-benzothiazole-6-carboxamide
1% inhibition at 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(phenylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
32% inhibition at 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyrazin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
11% inhibition at 0.01 mM
N-[2-[(naphthalen-2-ylmethyl)amino]ethyl]-2-[(pyridin-2-ylcarbonyl)amino]-1,3-benzothiazole-6-carboxamide
37% inhibition at 0.01 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]azetidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
14% inhibition at 0.01 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
27% inhibition at 0.01 mM
N-[6-([3-[(naphthalen-2-ylmethyl)amino]pyrrolidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
36% inhibition at 0.01 mM
N-[6-([4-[(naphthalen-2-ylmethyl)amino]piperidin-1-yl]carbonyl)-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
27% inhibition at 0.01 mM
N-[6-[(4-[[(naphthalen-2-ylmethyl)amino]methyl]piperidin-1-yl)carbonyl]-1,3-benzothiazol-2-yl]cyclohexanecarboxamide
32% inhibition at 0.01 mM
N-[[3'-(6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-5(4H)-ylmethyl)biphenyl-3-yl]methyl]-2-(pyridin-3-yl)ethanamine
-
palmitic acid
IC50 in the range 1-100 mM
S-(2-bromotetradecanoyl)-CoA
IC50 below 1 mM
S-(2-ketopentadecyl)-CoA
IC50: 0.00006 mM
tetradecyl trimethylammonium bromide
IC50 above 100 mM
tetradecyl triphenylphosphonium bromide
IC50 above 100 mM
DDD85646
-
-
factor NIP71
-
strong inhibition in a concentration dependent manner, noncompetitive
-
factor NIP71
-
bovine brain inhibitor protein
-
additional information
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
inhibition mechanism
-
additional information
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
development of specific anti-protozoan inhibitors against NMT, specificity over the human isozymes, component screening, structure-activity relationships, overview
-
additional information
-
2D and 3D quantitative structure-activity relationship (QSAR) studies on a series of benzothiophene derivatives as Plasmodium falciparum NMT and human NMT inhibitors. The polar interactions (electrostatic and hydrogen-bonding properties) as the major molecular features that affected the inhibitory activity and selectivity
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
N-Myristoyltransferase overexpression in human colorectal adenocarcinomas.
Brain Neoplasms
Expression of N-myristoyltransferase in human brain tumors.
Breast Neoplasms
Investigation of Novel Regulation of N-myristoyltransferase by Mammalian Target of Rapamycin in Breast Cancer Cells.
Breast Neoplasms
N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target.
Breast Neoplasms
NMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway.
Candidiasis
Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 2.
Carcinogenesis
Elevated N-myristoyltransferase activity and expression in oral squamous cell carcinoma.
Carcinogenesis
Expression of N-myristoyltransferase in human brain tumors.
Carcinogenesis
Expression of N-myristoyltransferase inhibitor protein and its relationship to c-Src levels in human colon cancer cell lines.
Carcinogenesis
Increased N-myristoyltransferase activity observed in rat and human colonic tumors.
Carcinogenesis
Phosphorylation and dephosphorylation of human myristoyltransferase type 1.
Carcinogenesis
Phosphorylation of human N-myristoyltransferase by N-myristoylated SRC family tyrosine kinase members.
Carcinogenesis
Requirement of N-myristoyltransferase 1 in the development of monocytic lineage.
Carcinoma
Elevated N-myristoyltransferase activity and expression in oral squamous cell carcinoma.
Carcinoma
Expression of N-myristoyltransferase in human brain tumors.
Carcinoma
High expression of methionine aminopeptidase 2 in human colorectal adenocarcinomas.
Carcinoma
Increased expression of N-myristoyltransferase in gallbladder carcinomas.
Carcinoma
Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.
Chagas Disease
The N-myristoylome of Trypanosoma cruzi.
Colonic Neoplasms
Expression of N-myristoyltransferase inhibitor protein and its relationship to c-Src levels in human colon cancer cell lines.
Colonic Neoplasms
Increased N-myristoyltransferase activity observed in rat and human colonic tumors.
Colonic Neoplasms
N-myristoyltransferase 2 expression in human colon cancer: cross-talk between the calpain and caspase system.
Colonic Neoplasms
N-myristoyltransferase: a potential novel diagnostic marker for colon cancer.
Colonic Neoplasms
Role of calpain and caspase system in the regulation of N-myristoyltransferase in human colon cancer (Review).
Colonic Neoplasms
The Potential Use of N-Myristoyltransferase as a Biomarker in the Early Diagnosis of Colon Cancer.
Common Cold
Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus.
Communicable Diseases
A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes.
Communicable Diseases
In silico identification of microRNAs predicted to regulate N-myristoyltransferase and Methionine Aminopeptidase 2 functions in cancer and infectious diseases.
Communicable Diseases
Validation and Invalidation of Chemical Probes for the Human N-myristoyltransferases.
Diabetes Mellitus
Membrane-associated N-myristoyltransferase activity is reduced in obese (fa/fa) Zucker rat liver.
Diphtheria
Naturally-occurring anti-thymocyte autoantibody which identifies a restricted CD4+CD8+CD3-/lo/int thymocyte subpopulation exhibits extensive polyspecificity.
Endodermal Sinus Tumor
A radioresistant variant cell line, NMT-1R, isolated from a radiosensitive rat yolk sac tumour cell line, NMT-1: differences of early radiation-induced morphological changes, especially apoptosis.
Endodermal Sinus Tumor
Combined effect of hyperthermia at 42 degrees C and irradiation dose of 2 Gy on two rat yolk sac tumor cell lines with different radio-thermosensitivity in vitro.
Endodermal Sinus Tumor
Establishment and characterization of a rat yolk sac tumor cell line, NMT-1, producing alpha-fetoprotein, with potential for lymphatic metastasis.
Endodermal Sinus Tumor
Potentially lethal damage repair and its inhibitory effect of caffeine in two yolk sac tumor cell lines with different radiosensitivities.
Epilepsy
Expression of myristoyltransferase and its interacting proteins in epilepsy.
Epilepsy
Myristoyltransferase and calcineurin: novel molecular therapeutic target for epilepsy.
glycylpeptide n-tetradecanoyltransferase deficiency
N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation.
Hepatitis B
In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses.
Infections
Down-regulation of N-myristoyl transferase expression in human T-cell line CEM by human immunodeficiency virus type-1 infection.
Infections
N-Myristoyltransferase as a Glycine and Lysine Myristoyltransferase in Cancer, Immunity, and Infections.
Infections
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs.
Leishmaniasis
Multiple chemical scaffolds inhibit a promising Leishmania drug target.
Leishmaniasis
N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis.
Leishmaniasis
Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites.
Leishmaniasis
QSAR and Pharmacophore Modeling of Nitrogen Heterocycles as Potent Human N-Myristoyltransferase (Hs-NMT) Inhibitors.
Leishmaniasis
Structure-based design of potent and selective Leishmania N-myristoyltransferase inhibitors.
Leishmaniasis, Visceral
N-myristoyltransferase from Leishmania donovani: structural and functional characterisation of a potential drug target for visceral leishmaniasis.
Leukemia
Myristoyl-CoA:protein N-myristoyltransferase activity in cancer cells. Purification and characterization of a cytosolic isoform from the murine leukemia cell line L1210.
Leukemia
N-myristoyl-transferase activity in cancer cells. Solubilization, specificity and enzymatic inhibition of a N-myristoyl transferase from L1210 microsomes.
Leukemia, Erythroblastic, Acute
A comparative analysis of the kinetic mechanism and peptide substrate specificity of human and Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase.
Leukemia, Erythroblastic, Acute
Comparison of the acyl chain specificities of human myristoyl-CoA synthetase and human myristoyl-CoA:protein N-myristoyltransferase.
Lymphatic Metastasis
A radioresistant variant cell line, NMT-1R, isolated from a radiosensitive rat yolk sac tumour cell line, NMT-1: differences of early radiation-induced morphological changes, especially apoptosis.
Lymphatic Metastasis
Establishment and characterization of a rat yolk sac tumor cell line, NMT-1, producing alpha-fetoprotein, with potential for lymphatic metastasis.
Malaria
Characterization of N-myristoyltransferase from Plasmodium falciparum.
Malaria
Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP).
Malaria
Design and synthesis of inhibitors of Plasmodium falciparum N-myristoyltransferase, a promising target for antimalarial drug discovery.
Malaria
Discovery of pyridyl-based inhibitors of Plasmodium falciparum N-myristoyltransferase.
Malaria
N-Myristoylation as a Drug Target in Malaria: Exploring the Role of N-Myristoyltransferase Substrates in the Inhibitor Mode of Action.
Malaria
N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis.
Malaria
New insight-guided approaches to detect, cure, prevent and eliminate malaria.
Malaria
Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites.
Malaria
QSAR and Pharmacophore Modeling of Nitrogen Heterocycles as Potent Human N-Myristoyltransferase (Hs-NMT) Inhibitors.
Malaria
QSAR studies on benzothiophene derivatives as Plasmodium falciparum N-myristoyltransferase inhibitors: Molecular insights into affinity and selectivity.
Malaria
Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach.
Melanoma
Palladium based nanoparticles for the treatment of advanced melanoma.
Mycoses
Design, Synthesis, Antifungal Activity and Molecular Docking of Thiochroman-4-one Derivatives.
Mycoses
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics.
Myositis
Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
Neoplasm Metastasis
Establishment and characterization of a rat yolk sac tumor cell line, NMT-1, producing alpha-fetoprotein, with potential for lymphatic metastasis.
Neoplasms
A fluorescence-based assay for N-myristoyltransferase activity.
Neoplasms
A radioresistant variant cell line, NMT-1R, isolated from a radiosensitive rat yolk sac tumour cell line, NMT-1: differences of early radiation-induced morphological changes, especially apoptosis.
Neoplasms
A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes.
Neoplasms
Combined effect of hyperthermia at 42 degrees C and irradiation dose of 2 Gy on two rat yolk sac tumor cell lines with different radio-thermosensitivity in vitro.
Neoplasms
Establishment and characterization of a rat yolk sac tumor cell line, NMT-1, producing alpha-fetoprotein, with potential for lymphatic metastasis.
Neoplasms
In silico identification of microRNAs predicted to regulate N-myristoyltransferase and Methionine Aminopeptidase 2 functions in cancer and infectious diseases.
Neoplasms
Increased N-myristoyltransferase activity observed in rat and human colonic tumors.
Neoplasms
Myristoyl-CoA:protein N-myristoyltransferase activity in cancer cells. Purification and characterization of a cytosolic isoform from the murine leukemia cell line L1210.
Neoplasms
Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review).
Neoplasms
N-myristoyl-transferase activity in cancer cells. Solubilization, specificity and enzymatic inhibition of a N-myristoyl transferase from L1210 microsomes.
Neoplasms
N-Myristoyltransferase as a Glycine and Lysine Myristoyltransferase in Cancer, Immunity, and Infections.
Neoplasms
N-Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and Apoptosis in Cancer Cells.
Neoplasms
Overexpression of Akt/PKB modulates N-myristoyltransferase activity in cancer cells.
Neoplasms
Potential role of N-myristoyltransferase in cancer.
Neoplasms
Potentially lethal damage repair and its inhibitory effect of caffeine in two yolk sac tumor cell lines with different radiosensitivities.
Neoplasms
QSAR and Pharmacophore Modeling of Nitrogen Heterocycles as Potent Human N-Myristoyltransferase (Hs-NMT) Inhibitors.
Neoplasms
Targeting N-myristoylation for therapy of B-cell lymphomas.
Neoplasms
Validation and Invalidation of Chemical Probes for the Human N-myristoyltransferases.
Neoplasms
[A study on the relationship between sensitivity to CDDP and inducibility of metallothionein and glutathione of genitourinary tumors]
Neoplasms, Glandular and Epithelial
Expression of N-myristoyltransferase in human brain tumors.
Neoplasms, Glandular and Epithelial
Expression of N-myristoyltransferase inhibitor protein and its relationship to c-Src levels in human colon cancer cell lines.
Neoplasms, Glandular and Epithelial
Increased N-myristoyltransferase activity observed in rat and human colonic tumors.
Parasitic Diseases
Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP).
Parasitic Diseases
Discovery of pyridyl-based inhibitors of Plasmodium falciparum N-myristoyltransferase.
Parasitic Diseases
Diverse modes of binding in structures of Leishmania major N-myristoyltransferase with selective inhibitors.
Parkinsonian Disorders
Increased myocardial N-myristoyltransferase activity in rotenone model of Parkinsonism.
Pneumonia
Expression and activity of N-myristoyltransferase in lung inflammation of cattle and its role in neutrophil apoptosis.
Reperfusion Injury
QSAR and Pharmacophore Modeling of Nitrogen Heterocycles as Potent Human N-Myristoyltransferase (Hs-NMT) Inhibitors.
Squamous Cell Carcinoma of Head and Neck
Elevated N-myristoyltransferase activity and expression in oral squamous cell carcinoma.
Trypanosomiasis, African
Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors.
Trypanosomiasis, African
Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode.
Trypanosomiasis, African
Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors.
Trypanosomiasis, African
Global Profiling and Inhibition of Protein Lipidation in Vector and Host Stages of the Sleeping Sickness Parasite Trypanosoma brucei.
Trypanosomiasis, African
Identification and structure solution of fragment hits against kinetoplastid N-myristoyltransferase.
Trypanosomiasis, African
Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis.
Trypanosomiasis, African
N-myristoyltransferase inhibitors as new leads to treat sleeping sickness.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.196 - 0.33
HIV1 Gag protein N-terminal peptide
-
0.0015 - 0.011
HIV1 Nef protein N-terminal peptide
-
0.2
cAMP-dependent protein kinase-derived peptide
-
-
-
0.0144 - 0.0257
HIV-1 negative regulatory factor
-
0.196 - 0.33
HIV1 Gag protein N-terminal peptide
-
0.0015 - 0.011
HIV1 Nef protein N-terminal peptide
-
0.00057 - 0.765
myristoyl-CoA
0.00276 - 0.00277
peptide Hs pp60src(2-9)
-
additional information
additional information
-
0.196
HIV1 Gag protein N-terminal peptide
pH 7.4, 37°C, isozyme NMT2
-
0.33
HIV1 Gag protein N-terminal peptide
pH 7.4, 37°C, isozyme NMT1
-
0.0015
HIV1 Nef protein N-terminal peptide
pH 7.4, 37°C, isozyme NMT2
-
0.011
HIV1 Nef protein N-terminal peptide
pH 7.4, 37°C, isozyme NMT1
-
0.0144
HIV-1 negative regulatory factor
N-terminal truncation mutant, pH 7.5, 25°C
-
0.0257
HIV-1 negative regulatory factor
wild-type, pH 7.5, 25°C
-
0.196
HIV1 Gag protein N-terminal peptide
pH 7.4, 37°C, isozyme NMT2
-
0.33
HIV1 Gag protein N-terminal peptide
pH 7.4, 37°C, isozyme NMT1
-
0.0015
HIV1 Nef protein N-terminal peptide
pH 7.4, 37°C, isozyme NMT2
-
0.011
HIV1 Nef protein N-terminal peptide
pH 7.4, 37°C, isozyme NMT1
-
0.00057
myristoyl-CoA
wild-type, pH 7.5, 25°C
0.00104
myristoyl-CoA
N-terminal truncation mutant, pH 7.5, 25°C
0.00724
myristoyl-CoA
-
pH 7.9-8.0, 25°C, isozyme NMT2
0.00824
myristoyl-CoA
-
pH 7.9-8.0, 25°C, isozyme NMT1
0.018
myristoyl-CoA
wild-type, pH 8.0, 30°C
0.02
myristoyl-CoA
mutant V181A, pH 8.0, 30°C
0.033
myristoyl-CoA
mutant Y180F/N246A, pH 8.0, 30°C
0.051
myristoyl-CoA
mutant K107E/K252E, pH 8.0, 30°C
0.054
myristoyl-CoA
mutant V181L, pH 8.0, 30°C
0.187
myristoyl-CoA
mutant Y192A, pH 8.0, 30°C
0.765
myristoyl-CoA
mutant Y180A, pH 8.0, 30°C
0.00276
peptide Hs pp60src(2-9)
-
pH 7.9-8.0, 25°C, isozyme NMT1
-
0.00277
peptide Hs pp60src(2-9)
-
pH 7.9-8.0, 25°C, isozyme NMT2
-
additional information
additional information
NMT1 and NMT2 have 30 and 130fold lower Km values for Nef than Gag, respectively. Michaelis-Menten kinetics, and kinetic modelling of isozymes, overview
-
additional information
additional information
NMT1 and NMT2 have 30 and 130fold lower Km values for Nef than Gag, respectively. Michaelis-Menten kinetics, and kinetic modelling of isozymes, overview
-
additional information
additional information
-
NMT1 and NMT2 have 30 and 130fold lower Km values for Nef than Gag, respectively. Michaelis-Menten kinetics, and kinetic modelling of isozymes, overview
-
additional information
additional information
NMT1 and NMT2 have 30 and 130fold lower Km values for Nef than Gag, respectively. Michaelis-Menten kinetics, and kinetic modelling of isozymes, overview
-
additional information
additional information
NMT1 and NMT2 have 30 and 130fold lower Km values for Nef than Gag, respectively. Michaelis-Menten kinetics, and kinetic modelling of isozymes, overview
-
additional information
additional information
-
NMT1 and NMT2 have 30 and 130fold lower Km values for Nef than Gag, respectively. Michaelis-Menten kinetics, and kinetic modelling of isozymes, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Duronio, R.J.; Read, S.I.; Gordon, J.I.
Mutations of human myristoyl-CoA:protein N-myristoyltransferase cause temperature-sensitive myristic acid auxotrophy in Saccharomyces cerevisiae
Proc. Natl. Acad. Sci. USA
89
4129-4133
1992
Homo sapiens
brenda
Raju, R.V.S.; Datla, R.S.S.; Sharma, R.K.
Expression of human N-myristoyltransferase in Escherichia coli. Comparison with N-myristoyltransferases expressed in different tissues
Mol. Cell. Biochem.
155
69-76
1996
Homo sapiens
brenda
McIlhinney, R.A.J.; McGlone, K.
Immunocytochemical characterization and subcellular localization of human myristoyl-CoA: protein N-myristoyltransferase in HeLa cells
Exp. Cell Res.
223
348-356
1996
Homo sapiens
brenda
Young, K.; Egerton, M.; Camble, R.; White, A.; McIlhinney, R.A.J.
Immunochemical characterization of human N-myristoyltransferase: evidence for more than one form of the enzyme
Biochem. Soc. Trans.
25
S631
1997
Homo sapiens
brenda
Giang, D.K.; Cravatt, B.F.
A second mammalian N-myristoyltransferase
J. Biol. Chem.
273
6595-6598
1998
Homo sapiens (O60551), Homo sapiens (P30419), Homo sapiens, Mus musculus (O70310), Mus musculus (O70311), Mus musculus
brenda
Raju, R.V.S.; Datla, R.S.S.; Warrington, R.C.; Sharma, R.K.
Effects of L-histidine and its structural analogs on human N-myristoyltransferase activity and importance of EEVEH amino acid sequence for enzyme activity
Biochemistry
37
14928-14936
1998
Homo sapiens, Rattus norvegicus
brenda
McIlhinney, R.A.; Young, K.; Egerton, M.; Camble, R.; White, A.; Soloviev, M.
Characterization of human and rat brain myristoyl-CoA:protein N-myristoyltransferase: evidence for an alternative splice variant of the enzyme
Biochem. J.
333
491-495
1998
Homo sapiens, Rattus norvegicus
-
brenda
Pasha, M.K.; Dimmock, J.R.; Hollenberg, M.D.; Sharma, R.K.
Enhanced activity of human N-myristoyltransferase by dimethyl sulfoxide and related solvents in the presence of serine/threonine-containing peptide substrates
Biochem. Pharmacol.
64
1461-1467
2002
Homo sapiens
brenda
Selvakumar, P.; Lakshmikuttyamma, A.; Lawman, Z.; Bonham, K.; Dimmock, J.R.; Sharma, R.K.
Expression of methionine aminopeptidase 2,N-myristoyltransferase, and N-myristoyltransferase inhibitor protein 71 in HT29
Biochem. Biophys. Res. Commun.
322
1012-1017
2004
Homo sapiens
brenda
Hill, B.T.; Skowronski, J.
Human N-myristoyltransferases form stable complexes with lentiviral nef and other viral and cellular substrate proteins
J. Virol.
79
1133-1141
2005
Homo sapiens
brenda
Ma, H.H.; Yang, L.; Yang, X.Y.; Xu, Z.P.; Li, B.L.
Bacterial expression, purification, and in vitro N-myristoylation of fusion hepatitis B virus preS1 with the native-type N-terminus
Protein Expr. Purif.
27
49-54
2003
Homo sapiens
brenda
Selvakumar, P.; Lakshmikuttyamma, A.; Charavaryamath, C.; Singh, B.; Tuchek, J.; Sharma, R.K.
Expression of myristoyltransferase and its interacting proteins in epilepsy
Biochem. Biophys. Res. Commun.
335
1132-1139
2005
Bos taurus, Saccharomyces cerevisiae, Candida sp. (in: Saccharomycetales), Oryctolagus cuniculus, Dictyostelium sp., Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Breuer, S.; Gerlach, H.; Kolaric, B.; Urbanke, C.; Opitz, N.; Geyer, M.
Biochemical indication for myristoylation-dependent conformational changes in HIV-1 Nef
Biochemistry
45
2339-2349
2006
Homo sapiens
brenda
Yamazaki, K.; Kaneko, Y.; Suwa, K.; Ebara, S.; Nakazawa, K.; Yasuno, K.
Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure
Bioorg. Med. Chem.
13
2509-2522
2005
Candida albicans (P30418), Candida albicans, Homo sapiens (P30419)
brenda
Selvakumar, P.; Sharma, R.K.
Phosphorylation and dephosphorylation of human myristoyltransferase type 1
Can. J. Physiol. Pharmacol.
84
707-712
2006
Homo sapiens (P30419), Homo sapiens
brenda
Selvakumar, P.; Smith-Winsor, E.; Bonham, K.; Sharma, R.K.
N-Myristoyltransferase 2 expression in human colon cancer: Cross-talk between the calpain and caspase system
FEBS Lett.
580
2021-2026
2006
Homo sapiens
brenda
Selvakumar, P.; Sharma, R.K.
Role of calpain and caspase system in the regulation of N-myristoyltransferase in human colon cancer (Review)
Int. J. Mol. Med.
19
823-827
2007
Homo sapiens (O60551), Homo sapiens
brenda
Ducker, C.E.; Upson, J.J.; French, K.J.; Smith, C.D.
Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis
Mol. Cancer Res.
3
463-476
2005
Homo sapiens (O60551), Homo sapiens (P30419), Homo sapiens
brenda
Lu, Y.; Selvakumar, P.; Ali, K.; Shrivastav, A.; Bajaj, G.; Resch, L.; Griebel, R.; Fourney, D.; Meguro, K.; Sharma, R.K.
Expression of N-myristoyltransferase in human brain tumors
Neurochem. Res.
30
9-13
2005
Homo sapiens (O60551), Homo sapiens (P30419), Homo sapiens
brenda
Selvakumar, P.; Lakshmikuttyamma, A.; Shrivastav, A.; Das, S.B.; Dimmock, J.R.; Sharma, R.K.
Potential role of N-myristoyltransferase in cancer
Prog. Lipid Res.
46
1-36
2007
Oryctolagus cuniculus, Homo sapiens (O60551), Homo sapiens (P30419), Homo sapiens, Saccharomyces cerevisiae (P14743), Bos taurus (P31717), Bos taurus (Q9N181), Rattus norvegicus (Q8K1Q0)
brenda
Seaton, K.; Smith, C.
N-Myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef
J. Gen. Virol.
89
288-296
2008
Homo sapiens (O60551), Homo sapiens (P30419), Homo sapiens
brenda
Shrivastav, A.; Varma, S.; Lawman, Z.; Yang, S.H.; Ritchie, S.A.; Bonham, K.; Singh, S.M.; Saxena, A.; Sharma, R.K.
Requirement of N-myristoyltransferase 1 in the development of monocytic lineage
J. Immunol.
180
1019-1028
2008
Homo sapiens, Mus musculus (O70310), Mus musculus (O70311), Mus musculus
brenda
Lakshmikuttyamma, A.; Selvakumar, P.; Tuchek, J.; Sharma, R.
Myristoyltransferase and calcineurin: novel molecular therapeutic target for epilepsy
Prog. Neurobiol.
84
77-84
2008
Homo sapiens
brenda
Goncalves, V.; Brannigan, J.A.; Thinon, E.; Olaleye, T.O.; Serwa, R.; Lanzarone, S.; Wilkinson, A.J.; Tate, E.W.; Leatherbarrow, R.J.
A fluorescence-based assay for N-myristoyltransferase activity
Anal. Biochem.
421
342-344
2012
Homo sapiens
brenda
Morgan, C.R.; Miglionico, B.V.; Engen, J.R.
Effects of HIV-1 Nef on human N-myristoyltransferase 1
Biochemistry
50
3394-3403
2011
Homo sapiens
brenda
Kumar, S.; Singh, B.; Dimmock, J.R.; Sharma, R.K.
N-myristoyltransferase in the leukocytic development processes
Cell Tissue Res.
345
203-211
2011
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Brand, S.; Cleghorn, L.A.; McElroy, S.P.; Robinson, D.A.; Smith, V.C.; Hallyburton, I.; Harrison, J.R.; Norcross, N.R.; Spinks, D.; Bayliss, T.; Norval, S.; Stojanovski, L.; Torrie, L.S.; Frearson, J.A.; Brenk, R.; Fairlamb, A.H.; Ferguson, M.A.; Read, K.D.; Wyatt, P.G.; Gilbert, I.H.
Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors
J. Med. Chem.
55
140-152
2012
Homo sapiens, Trypanosoma brucei
brenda
Bell, A.S.; Mills, J.E.; Williams, G.P.; Brannigan, J.A.; Wilkinson, A.J.; Parkinson, T.; Leatherbarrow, R.J.; Tate, E.W.; Holder, A.A.; Smith, D.F.
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs
PLoS Negl. Trop. Dis.
6
e1625
2012
Trypanosoma brucei (D0A003), Trypanosoma brucei, Leishmania donovani (D0AB09), Leishmania donovani, Homo sapiens (O60551), Homo sapiens (P30419), Homo sapiens, Plasmodium falciparum (Q8ILW6), Plasmodium falciparum
brenda
Ohta, H.; Takamune, N.; Kishimoto, N.; Shoji, S.; Misumi, S.
N-Myristoyltransferase 1 enhances human immunodeficiency virus replication through regulation of viral RNA expression level
Biochem. Biophys. Res. Commun.
463
988-993
2015
Homo sapiens
brenda
Flamm, A.G.; Le Roux, A.L.; Mateos, B.; Diaz-Lobo, M.; Storch, B.; Breuker, K.; Konrat, R.; Pons, M.; Coudevylle, N.
N-Lauroylation during the expression of recombinant N-myristoylated proteins: implications and solutions
ChemBioChem
17
82-89
2016
Homo sapiens
brenda
Perinpanayagam, M.; Beauchamp, E.; Martin, D.; Sim, J.; Yap, M.; Berthiaume, L.
Regulation of co-and post-translational myristoylation of proteins during apoptosis: Interplay of N-myristoyltransferases and caspases
FASEB J.
27
811-821
2013
Homo sapiens
brenda
Olaleye, T.O.; Brannigan, J.A.; Roberts, S.M.; Leatherbarrow, R.J.; Wilkinson, A.J.; Tate, E.W.
Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites
Org. Biomol. Chem.
12
8132-8137
2014
Plasmodium falciparum, Plasmodium vivax (A5K1A2), Leishmania donovani (D0AB09), Homo sapiens (P30419), Homo sapiens, Plasmodium vivax Salvador I (A5K1A2)
brenda
Kumar, S.; Sharma, R.
N-terminal region of the catalytic domain of human N-myristoyltransferase 1 acts as an inhibitory module
PLoS ONE
10
e0127661
2015
Homo sapiens (P30419), Homo sapiens
brenda
Garcia, M.; de Oliveira, A.; Bueno, R.; Nogueira, V.; de Souza, G.; Guido, R.
QSAR studies on benzothiophene derivatives as Plasmodium falciparum N-myristoyltransferase inhibitors Molecular insights into affinity and selectivity
Drug Dev. Res.
2020
1-21
2020
Homo sapiens, Plasmodium falciparum
brenda
Soupene, E.; Kao, J.; Cheng, D.; Wang, D.; Greninger, A.; Knudsen, G.; DeRisi, J.; Kuypers, F.
Association of NMT2 with the acyl-CoA carrier ACBD6 protects the N-myristoyltransferase reaction from palmitoyl-CoA
J. Lipid Res.
57
288-298
2016
Homo sapiens (O60551), Homo sapiens
brenda
Goncalves, V.; Brannigan, J.; Laporte, A.; Bell, A.; Roberts, S.; Wilkinson, A.; Leatherbarrow, R.; Tate, E.
Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase
MedChemComm
8
191-197
2017
Plasmodium falciparum, Plasmodium vivax (A5K1A2), Plasmodium vivax, Homo sapiens (O60551), Homo sapiens (P30419), Plasmodium vivax Salvador I (A5K1A2)
brenda
Mousnier, A.; Bell, A.S.; Swieboda, D.P.; Morales-Sanfrutos, J.; Perez-Dorado, I.; Brannigan, J.A.; Newman, J.; Ritzefeld, M.; Hutton, J.A.; Guedan, A.; Asfor, A.S.; Robinson, S.W.; Hopkins-Navratilova, I.; Wilkinson, A.J.; Johnston, S.L.; Leatherbarrow, R.J.; Tuthill, T.J.; Solari, R.; Tate, E.W.
Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus
Nat. Chem.
10
599-606
2018
Homo sapiens (O60551), Homo sapiens (P30419), Homo sapiens
brenda
Dian, C.; Perez-Dorado, I.; Riviere, F.; Asensio, T.; Legrand, P.; Ritzefeld, M.; Shen, M.; Cota, E.; Meinnel, T.; Tate, E.; Giglione, C.
High-resolution snapshots of human N-myristoyltransferase in action illuminate a mechanism promoting N-terminal Lys and Gly myristoylation
Nat. Commun.
11
1132
2020
Homo sapiens (P30419), Homo sapiens
brenda
Corbic Ramljak, I.; Stanger, J.; Real-Hohn, A.; Dreier, D.; Wimmer, L.; Redlberger-Fritz, M.; Fischl, W.; Klingel, K.; Mihovilovic, M.D.; Blaas, D.; Kowalski, H.
Cellular N-myristoyltransferases play a crucial picornavirus genus-specific role in viral assembly, virion maturation, and infectivity
PLoS Pathog.
14
e1007203
2018
Homo sapiens (P30419), Homo sapiens
brenda
Jacquier, M.; Kuriakose, S.; Bhardwaj, A.; Zhang, Y.; Shrivastav, A.; Portet, S.; Varma Shrivastav, S.
Investigation of novel regulation of N-myristoyltransferase by mammalian target of rapamycin in breast cancer cells
Sci. Rep.
8
12969
2018
Homo sapiens (P30419), Homo sapiens
brenda